Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

Strategy program "NEXT LEVEL"

DR. MARIOLA SÖHNGEN CEO MOLOGEN AG

Pursuant to Section 92 Para. 1 of the German Stock Corporation Act (AktG), the Executive Management Board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) indicates that the Company's provisional registered share capital is down to just €10,681,859.09 as of June 30, 2016 dated July 11, 2016 as a result of losses incurred. This means that half the... [more]

Half-year report 2016
Download

Balance as at 30 June 2016 (unaudited; German version only)
Download PDF

Quarterly Statement as at 31 March 2016
Download PDF

Annual Report 2015
Download PDF

Strategy Program “Next level”

Press Release
Presentation
FAQ